For generations, the mutations most responsible for driving cancer have hidden inside the cell, beyond the reach of the antibody therapies that transformed oncology. Researchers at KAIST in South Korea have now crossed that threshold, engineering an antibody that borrows the perceptual logic of T cells to recognize fragments of a mutated protein displayed on the cancer cell's surface — giving precision medicine a new way of seeing. Their target, KRAS(G12D), fuels some of the world's deadliest cancers and was long deemed untreatable by antibody-based means. If the underlying computational metho